Novartis' Kisqali Impresses In Premenopausal Breast Cancer As Market Crowds
Updated data from the MONALEESA-7 study shows the extent of its progression-free survival benefit in premenopausal women with advanced breast cancer; supplemental filings are planned.
You may also be interested in...
Novartis expected to give Joe Jimenez a good farewell gift; AbbVie says it is not planning major M&A to focus on risankizumab and upadacitinib, but Celgene is on the hunt for deals – will Juno be its next big buy?
Novartis has tempted Liz Barrett away from Pfizer to become CEO of Novartis Oncology, but the appointment of a new global drug development head at the Swiss multinational has yet to be announced.
Twenty-eight new products containing a total of 29 new active substances were authorized for marketing in the EU in 2017, very much line with the 2016 tally. As in that year, oncology dominated the 2017 approvals, which also included new drugs for rheumatoid arthritis, skin & blood disorders, and hepatitis C.